Published in Mol Ther on May 11, 2015
Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. Ther Clin Risk Manag (2015) 0.91
Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res (2016) 0.84
Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther (2016) 0.80
Advances in gene therapy for muscular dystrophies. F1000Res (2016) 0.75
Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice. Mol Ther Nucleic Acids (2016) 0.75
Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability. J Clin Invest (2016) 0.75
Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors. PLoS One (2016) 0.75
Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 20.27
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature (1997) 14.82
Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med (2004) 7.80
A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet (1997) 7.15
Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A (1997) 6.72
Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol (2013) 4.57
A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet (2007) 3.61
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A (2004) 3.34
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol (2009) 3.01
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol (2014) 2.15
Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem (2008) 2.11
The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain (1987) 2.07
mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci (1995) 2.06
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet (2008) 1.69
Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther (2009) 1.52
Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther (2010) 1.48
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther (2010) 1.20
Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation. Dis Model Mech (2009) 1.08
Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther (2010) 1.03
Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther (2010) 1.01
Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve (2009) 1.00
Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther (2011) 0.98
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics (2011) 0.92
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids (2012) 0.89
A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength. Exp Gerontol (2013) 0.89
Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice. Gene Ther (2014) 0.87